All News
Treat-to-Target in Gout and Cardiovascular Outcomes
A 5 year JAMA study shows that a treat-to-target (serum urate < 6 mg/dL) study finds that effective urate-lowering treatment (ULT) results in a significantly reduced cardiovascular risk in patients with gout.
Trends in Rheumatoid Arthritis Mortality
A recent study examines trends in rheumatoid arthritis (RA)-related mortality among U.S. postmenopausal women (aged 55 and older). They found RA mortality rates have declined, yet disparities in who is most affected persist, especially for white women, and those over 85 yrs of age.
Read Article
New content online: Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials https://t.co/nDxfWWgutC https://t.co/Z6JMojdBz4
Links:
NatRevRheumatol NatRevRheumatol ( View Tweet)
🧬 PAPA Syndrome: When Sterile Inflammation Mimics Infection
(Pyogenic Arthritis, Pyoderma gangrenosum, Acne)
•A rare monogenic autoinflammatory disease
•Caused by gain-of-function mutations in PSTPIP1
🧠 Pathophysiology
•Mutant PSTPIP1 → increased interaction with pyrin https://t.co/tJ4INdgfky
Ravi Kumar RheumattDoc ( View Tweet)
Rheum Poll> Which is the most difficult to treat RA (D2TRA) patient (despite aggressive Rx)?
Dr. John Cush RheumNow ( View Tweet)
BIOBADASER III Registry shows No Cancer Risk with b/tsDMARDs
A large, real-world cohort study of rheumatoid arthritis (RA) finds patients treated with biologic and targeted synthetic DMARDs (b/tsDMARDs) do not have an increased risk of cancer.
https://t.co/0oawv88Anq https://t.co/nrsok06gKV
Links:
Dr. John Cush RheumNow ( View Tweet)
Kick off 2026 with #RheumNowLive—two days of cutting-edge rheumatology, rapid-fire STEP talks, interactive Q&A, and real-world insights with Drs. Jack Cush, Arthur Kavanaugh, and a powerhouse faculty. Register: https://t.co/zh0aBDMfoP
@RheumNow
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
APPIPRA Study - Benefits of Early Treatment
Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped.
https://t.co/hgxj936CWn https://t.co/eJX3amp3Id
Links:
Dr. John Cush RheumNow ( View Tweet)
Turkish study of 128 Psoriatics (62 PSO, 66 PsA) found more periodontitis in PsA vs PSO (47% vs 31%; P=.058). Signif. higher levels of Dz activity seen for PSO (CPDAI: OR 1.38; P = .001) & enthesitis (MASES: OR 1.39; P < .001) if periodontitis present in PsA patients. https://t.co/d8OfarFWeG
Dr. John Cush RheumNow ( View Tweet)
What Is Restless Legs Syndrome? JAMA Patient Education handout. https://t.co/fCqArVxrSu https://t.co/WjFNWyr9Q2
Dr. John Cush RheumNow ( View Tweet)
Evaluation of pts w/ muscle weakness and elevated muscle enzymes https://t.co/faTWMscUzz https://t.co/Dcx8m4Ny7Y
Dr. John Cush RheumNow ( View Tweet)
“We will remember not the words of our enemies, but the silence of our friends.”
- Martin Luther King, Jr.
Dr. John Cush RheumNow ( View Tweet)
Drugs that may cause toxic myopathy, presenting as muscle dysfunction w/ weakness and elevated muscle enzymes and possibly confused w/ idiopathic inflammatory myopathies (IIM) - full read review of mimickers of myositis. https://t.co/1Yn3OXXEH6 https://t.co/HmQiYFSQMU
Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Anifrolumab in SLE
Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/EzaqS5q096
Dr. John Cush RheumNow ( View Tweet)
The 2025 Rheumatology Year in Review
The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders, ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines, and practices that https://t.co/71stL3X8my
Dr. John Cush RheumNow ( View Tweet)
ANAs and Autoantibodies
https://t.co/AANvCKeAl0 https://t.co/SSPUxMEuLh
Dr. John Cush RheumNow ( View Tweet)
Are JAK Inhibitors Better at Pain Relief in RA?
Among rheumatoid arthritis (RA) patients who responded to upadacitinib (Rinvoq) or adalimumab, those receiving upadacitinib had significantly less residual pain with treatment, according to a post hoc analysis of phase III trial https://t.co/QrbwlxIm3d
Dr. John Cush RheumNow ( View Tweet)
Review of Restless Legs Syndrome
JAMA has published a full review of RLS - restless leg syndrome - a frequent, but often unrecognized, cause of poor sleep and the resultant hazards of insomnia.
https://t.co/lPSMH3v7xS https://t.co/lbSfeNrfLz
Dr. John Cush RheumNow ( View Tweet)
Acupuncture in SpA metanalysis of 35 RCTs (2,591 AS pts) showed statistically significant improvements BASDAI score, BASFI score, ASDAS, VAS score, CRP level, and ESR level. Findings imited by high heterogeneity & the lack of large-scale, high-quality RCTs. https://t.co/gznAiNo0k4
Dr. John Cush RheumNow ( View Tweet)
Retrospective real-world study of 87 Behcets dz pts & inital Rx w/ IFX (n 45) or ADA (n 42) (2020 to 2025) & >60% were on AZA. Complete remission achieved in 76% (IFX) vs 79% (ADA) initially, & 89% vs 77% last visit. Same Rx retention but more relapses w/ IFX (38% v 17%) https://t.co/6FiuYe0GI9
Dr. John Cush RheumNow ( View Tweet)
